ABT ABBOTT LABORATORIES $176.8B

What they are doing

Diversified healthcare. Libre is a quarterly CGM franchise. The 10-K names data-management decision software. The Q2 call was Duo (glucose+ketone sensor), coverage, and pipeline hardware — not an AI discussion. Diagnostics / neuro digital health is strategy language. We are not scoring Abbott as if it were Dexcom. The 21 October 2026 call did not mention artificial intelligence. The miss is Ultreon 3.0, cleared 24 April 2026 (K253459). Abbott's own 510(k) says the software uses machine learning to mark calcium, lipid plaque, and the vessel wall during a coronary procedure, and to support stent size and position. The physician still decides. No case count and no outcome were given. The published score is still 4. The recommendation, not yet accepted, is Reach 2, Weight 3, Proof 2, total 7.

Why the score

• Reach 1 not 2: decision software is named. No second function we can point to.
• Weight 2 not 3: companion software is table stakes in CGM. Duo is a sensor.
• Proof 1 not 2: is sensor volume. No intelligence result.

What would move it next quarter: A case count or an outcome on Ultreon. Clearance alone will not move Proof past 2.

Open these first

Evidence